Phentolamine Eye Drops Reverses Pharmacologically Induced My
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
After a dilated eye examination, many patients experience symptoms of prolonged light sensitivity, blurred vision, and cycloplegia associated with pharmacological mydriasis. Phentolamine mesylate ophthalmic solution (PMOS) may expedite the reversal of mydriasis in patients, potentially facilitating return to functional vision and reducing barriers to obtaining dilated eye examinations.

The protracted reversal time after pharmacologically induced pupil dilation impairs vision. Researchers tested the hypothesis that PMOS rapidly reduces pupil diameter in this acute indication.

In this double-masked placebo-controlled, randomized, two-arm crossover phase 2b trial, the effects of one drop of 1% PMOS applied bilaterally in subjects who had their pupils dilated by one of two common mydriatic agents: 2.5% phenylephrine or 1% tropicamide were evaluated. End points included change in pupil diameter, percent of subjects returning to baseline pupil diameter, and accommodative function at multiple time points.

--31 subjects completed the study (15 dilated with phenylephrine and 16 with tropicamide). Change in pupil diameter from baseline at 2 hours after maximal dilation with 1% PMOS was -1.69 mm and was significantly greater in magnitude compared with placebo for every time point beyond 30 minutes.

--At 2 hours, a greater percentage of study eyes given 1% PMOS returned to baseline pupil diameter compared with placebo (29 vs. 13%), which was this also seen at 4 hours.

--More subjects treated with PMOS in the tropicamide subgroup had at least one eye returning to baseline accommodative amplitude at 2 hours (63 vs. 38%).

--There were no severe adverse events, with only mild to moderate conjunctival hyperemia that resolved in most patients by 6 hours.

Phentolamine mesylate ophthalmic solution at 1% reversed medically induced pupil dilation faster than placebo therapy, regardless of which mydriatic was used (adrenergic agonists or cholinergic blockers), and had a tolerable safety profile.